UnitedHealthcare
10
0
8
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
10.0%
1 terminated/withdrawn out of 10 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
Role: collaborator
Standard Care Coordination Expansion Pilot
Role: lead
Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix
Role: collaborator
Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms
Role: collaborator
Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
Role: collaborator
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
Role: collaborator
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
Role: collaborator
Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
Role: collaborator
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV
Role: collaborator
Bikes For Life: Measuring the Effects of a Bicycle Distribution Program on Pediatric Obesity
Role: collaborator
All 10 trials loaded